Patent application number | Description | Published |
20100051572 | CHILD-RESISTANT CANISTER - A child-resistant canister includes a container and a closure configured to mount on the container to close an opening into an interior region formed in the container. The closure includes a lid and a lid anchor coupled to the lid. The lid anchor is configured to mate with a closure retainer included in the container to retain the closure in a mounted position on the container. | 03-04-2010 |
20100102094 | PACKAGE WITH FLUID-DISPENSER SYSTEM - A package includes a container and a removable cap coupled to a filler neck of the container. The package also includes a fluid dispenser coupled to the filler neck to regulate discharge of fluid material from an interior region of the container. | 04-29-2010 |
20100200533 | VIAL WITH PUSH-BUTTON RELEASE CLOSURE - A child-resistant package includes a vial and a closure configured to mount on the vial to cover a mouth opening into a product-storage chamber of the vial. A child-resistant feature cooperates with the closure and the vial to prevent unwanted removal of the closure from the vial. | 08-12-2010 |
20100252478 | CHILD-RESISTANT PACKAGE WITH PIVOTABLE BLISTER CARD - A child-resistant package includes a case and blister cards. The blister cards are mounted for movement between stored positions inside the case and exposed positions outside the case. | 10-07-2010 |
20100264054 | CHILD-RESISTANT MULTI-BLISTER CARD CASE - A child-resistant package includes a case and blister cards. The blister cards are mounted for movement between stored positions inside the case and exposed positions outside the case. | 10-21-2010 |
20110259915 | Product-Dispensing Container With Pressurizable and Collapsible Product-Storage Bag - A container includes a bottle formed to include an interior region and a collapsible bag in the interior region. The collapsible bag is formed to include a chamber for holding a dispensable product. A dispenser is coupled to the bottle and arranged to communicate with dispensable product held in the collapsible bag. The dispenser is operable by a consumer to discharge the dispensable product from the collapsible bag. | 10-27-2011 |
Patent application number | Description | Published |
20100081878 | Integrated Locking Device With Active Sealing - Endoscope assemblies, biopsy caps, and methods for making and using the same. An example endoscope assembly may include an endoscope having a channel formed therein and a port that provides access to the channel. A cap may be coupled to the port. The cap may include a base and an outer shell. A locking member may be coupled to the outer shell. An inner seal member may be disposed within the outer shell. One or more openings may extend through the cap and into the channel. An actuator may be coupled to the base for shifting the inner seal member between an unsealed configuration and a sealed configuration. | 04-01-2010 |
20100087705 | Integrated Locking Device With Passive Sealing - Endoscope assemblies, biopsy caps, and methods for making and using the same. An example endoscope assembly may include an endoscope having a channel formed therein and a port that provides access to the channel. A cap may be coupled to the port. The cap may include a base having a securing member for securing the cap to the port, an outer shell, a locking member coupled to the outer shell, an inner seal member, and a central opening that extends to the channel. The inner seal member may include a plurality of flaps. | 04-08-2010 |
20100087710 | Integrated Locking Device With Fluid Control - Endoscope assemblies, biopsy caps, and methods for making and using the same. An example endoscope assembly may include an endoscope having a channel formed therein and a port that provides access to the channel. A cap may be coupled to the port. The cap may include a base having a securing member for securing the cap to the port. The cap may also include an outer shell, a locking member coupled to the outer shell, an inner seal member disposed within the outer shell, and one or more openings extending through the cap and into the channel. A fluid control region may be defined within the outer shell. | 04-08-2010 |
Patent application number | Description | Published |
20090139196 | WINDROW MERGER LIFT MECHANISM - A windrow merger lift mechanism having on a pair of rotational axes, skewed with respect to each other, to manipulate a merger apparatus between working and non-working positions. When the merger apparatus is in a first, or working position, the lift mechanism positions it to receive crop material from the conditioner rolls with minimal losses. When the merger apparatus is in a second, or non-working position, the lift mechanism positions the merger apparatus to allow crop material to be discharged from the header/conditioner with the same efficiency as a windrower having no installed merger attachment. The skewed axes of the merger lift mechanism optimize the merger position in both the working and non-working positions by moving the merger apparatus in four distinct, but related degrees of motion as the merger apparatus is moved between the positions. | 06-04-2009 |
20090313964 | FLOATING SWATHGATE - A floating swathgate for a cutting and conditioning header for a frame-supported tractor in which the angular attitude of the swathgate relative to an airborne stream of crop material being ejected from conditioner apparatus is varied as the header moves vertically with respect to the tractor to optimally direct the crop material toward a rearwardly disposed crop merger conveyor. As the header moves vertically, changes in the angular attitude of the swathgate direct the airborne crop material to generally the same location on the merger conveyor to minimize crop losses that typically occur with a fixed swathgate when the crop trajectory varies directly with the header vertical movement. | 12-24-2009 |
20090320432 | Windrow Merger Lift Mechanism - A windrow merger lift mechanism having on a pair of rotational axes, skewed with respect to each other, to manipulate a merger apparatus between working and non-working positions. When the merger apparatus is in a first, or working position, the lift mechanism positions it to receive crop material from the conditioner rolls with minimal losses. When the merger apparatus is in a second, or non-working position, the lift mechanism positions the merger apparatus to allow crop material to be discharged from the header/conditioner with the same efficiency as a windrower having no installed merger attachment. The skewed axes of the merger lift mechanism optimize the merger position in both the working and non-working positions by moving the merger apparatus in four distinct, but related degrees of motion as the merger apparatus is moved between the positions. | 12-31-2009 |
Patent application number | Description | Published |
20090286276 | METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS - The present invention provides methods for individualizing chemotherapy for cancer treatment, and particularly for evaluating a patient's responsiveness to one or more epidermal growth factor receptor (EGFR) inhibitors prior to treatment with such agents. Particularly, the invention provides an in vitro chemoresponse assay for predicting a patient's response to an EGFR inhibitor, such as an EGFR tyrosine kinase inhibitor or a molecule targeting the extracellular domain of EGFR. The method generally comprises culturing malignant cells from a patient's specimen (e.g., biopsy specimen), contacting the cultured cells with an EGFR inhibitor that is a candidate treatment for the patient, and evaluating the cultured cells for a response to the drug. In certain embodiments, monolayer(s) of malignant cells are cultured from explants prepared by mincing tumor tissue, and the cells of the monolayer are suspended and plated for chemosenstivity testing. The in vitro response to the drug as determined by the method of the invention is correlative with the patient's in vivo response upon receiving the EGFR inhibitor during chemotherapeutic treatment (e.g., in combination with other standardized or individualized chemotherapeutic regimen). | 11-19-2009 |
20100311084 | METHODS FOR PREDICTING A PATIENT'S RESPONSE TO EGFR INHIBITORS - The present invention provides methods for individualizing chemotherapy for cancer treatment, and particularly for evaluating a patient's responsiveness to one or more epidermal growth factor receptor (EGFR) inhibitors prior to treatment with such agents. Particularly, the invention provides an in vitro chemoresponse assay for predicting a patient's response to a monoclonal EGFR antibody, such as cetuximab. The method generally comprises culturing malignant cells from a patient's specimen (e.g., biopsy specimen), contacting the cultured cells with a monoclonal EGFR antibody that is a candidate treatment for the patient, and evaluating the cultured cells for a response to the drug. In certain embodiments, monolayer(s) of malignant cells are cultured from explants prepared by mincing tumor tissue, and the cells of the monolayer are suspended and plated for chemosenstivity testing. The in vitro response to the drug as determined by the method of the invention is correlative with the patient's in vivo response upon receiving the monoclonal EGFR antibody during chemotherapeutic treatment (e.g., in combination with other standardized or individualized chemotherapeutic regimen). | 12-09-2010 |
20110129822 | MULTI DRUG RESPONSE MARKERS FOR BREAST CANCER CELLS - The present invention provides methods for preparing a gene expression profile of a breast cancer cell, tumor, or cell line, where the gene expression profile may be evaluated for one or more gene expression signatures indicative of multidrug resistance. The signature may be indicative of resistance to one or more chemotherapeutic agents selected from a Taxol (e.g., Docetaxel or Paclitaxel), an antibiotic (e.g., Doxorubicin or Epirubicin), an antimetabolite (e.g., Fluorouracil and/or Gemcitabine), and an alkylating agent (e.g., Cyclophosphamide). Generally, the gene expression profile contains the level of expression for a plurality of genes listed in FIGS. | 06-02-2011 |
20110130302 | BIOLOGICAL PATHWAYS ASSOCIATED WITH CHEMOTHERAPY OUTCOME FOR BREAST CANCER - The present invention provides methods for preparing drug response and/or resistance profiles for breast tumor specimens, or cells derived therefrom. The drug response and/or resistance profiles are useful for determining effective chemotherapeutic agents for treatment of the tumor or cell to thereby individualize patient therapy. In other aspects, the invention provides a method for identifying a pathway or gene expression signature indicative of a breast cancer cell's sensitivity to a chemotherapeutic agent, which is useful for identifying a population response rate, or patient sub-population likely to respond to the drug candidate. | 06-02-2011 |
Patent application number | Description | Published |
20100143948 | CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS - The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient. | 06-10-2010 |
20120329086 | CHEMO-SENSITIVITY ASSAYS USING TUMOR CELLS EXHIBITING PERSISTENT PHENOTYPIC CHARACTERISTICS - The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring the progression of an individual patient malignancy. The assays, methods, tools and systems discussed herein represent an improved and unified system for monitoring and for identifying cellular and secreted markers, for screening cells to detect phenotypic and genotypic drift and for predicting chemotherapeutic response of patient tumor cells to at least one therapeutic agent. The assays, methods, tools and systems discussed herein also represent an improved and unified system for monitoring and for screening multiple pharmaceutical agents for efficacy and long term effect as to a specific patient. | 12-27-2012 |